Evidence map›Paper›PMID 41004263›Full record

ArticleAntimicrobial agents and chemotherapy2025

Characterization of new mouse models of acute and chronic

Ilham M Alshiraihi, Ha Lam, Brennen T Troyer, Kristina N Tran, Malik Zohaib Ali, Daryl K Conner, Abigail Godelfer, Camron Pearce, Mary Jackson, Marcela Henao-Tamayo and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Journal of bacteriology · 2026
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Ilham M Alshiraihi *Mycobacteria Research Laboratories, Non-Tuberculous Mycobacteria Center, Colorado State University, Fort Collins, Colorado, USA.
Ha Lam *Mycobacteria Research Laboratories, Non-Tuberculous Mycobacteria Center, Colorado State University, Fort Collins, Colorado, USA.
Brennen T TroyerMycobacteria Research Laboratories, Non-Tuberculous Mycobacteria Center, Colorado State University, Fort Collins, Colorado, USA.
Kristina N TranMycobacteria Research Laboratories, Non-Tuberculous Mycobacteria Center, Colorado State University, Fort Collins, Colorado, USA.
Malik Zohaib AliMycobacteria Research Laboratories, Non-Tuberculous Mycobacteria Center, Colorado State University, Fort Collins, Colorado, USA.
Daryl K ConnerMycobacteria Research Laboratories, Non-Tuberculous Mycobacteria Center, Colorado State University, Fort Collins, Colorado, USA.
Abigail GodelferMycobacteria Research Laboratories, Non-Tuberculous Mycobacteria Center, Colorado State University, Fort Collins, Colorado, USA.
Camron PearceMycobacteria Research Laboratories, Non-Tuberculous Mycobacteria Center, Colorado State University, Fort Collins, Colorado, USA.
Mary JacksonMycobacteria Research Laboratories, Non-Tuberculous Mycobacteria Center, Colorado State University, Fort Collins, Colorado, USA.ORCID 0000-0002-9212-0258
Marcela Henao-TamayoMycobacteria Research Laboratories, Non-Tuberculous Mycobacteria Center, Colorado State University, Fort Collins, Colorado, USA.
Sara E Maloney NorcrossTechnology Advancement and Commercialization, RTI International, Research Triangle Park, North Carolina, USA.
Bernd MeibohmDepartment of Pharmaceutical Sciences, University of Tennessee Health Science Center, Memphis, Tennessee, USA.ORCID 0000-0003-3923-3648
Richard E LeeDepartment of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.ORCID 0000-0002-2397-0443
Mercedes Gonzalez-JuarreroMycobacteria Research Laboratories, Non-Tuberculous Mycobacteria Center, Colorado State University, Fort Collins, Colorado, USA.ORCID 0000-0002-4045-2365
Andres Obregon-HenaoMycobacteria Research Laboratories, Non-Tuberculous Mycobacteria Center, Colorado State University, Fort Collins, Colorado, USA.ORCID 0000-0002-6496-6790

Funding

Spectinomycin analogs for NTM infectionsR01AI157312 · NIAID · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI LEE, RICHARD E. · 2020 to 2024
$4.1M
Inhaled tigecycline therapy for pulmonary M. abscessus infectionsR01AI155922 · NIAID · COLORADO STATE UNIVERSITY · PI GONZALEZ-JUARRERO, MERCEDES, MALONEY, SARA ELIZABETH · 2021 to 2025
$3.6M
Repurposing antimalarials for the treatment of NTM infectionsR01AI170504 · NIAID · COLORADO STATE UNIVERSITY · PI JACKSON, MARY · 2022 to 2025
$2.6M
Vectra Polaris microscope imaging systemS10OD030263 · OD · COLORADO STATE UNIVERSITY · PI GONZALEZ-JUARRERO, MERCEDES · 2021 to 2021
$452k
Cystic Fibrosis Foundation Therapeutics 1415315National Institute of Allergy and Infectious Diseases R01AI155922National Institute of Allergy and Infectious Diseases R01AI170504National Institute of Allergy and Infectious Diseases RO1AI157312NIAID NIH HHS R01 AI155922NIAID NIH HHS R01 AI157312NIAID NIH HHS R01 AI170504NIH HHS S10 OD030263NIH Office of the Director 1S10OD030263
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Anti-Bacterial AgentsMycobacterium abscessusMycobacterium Infections, NontuberculousAnimalsDisease Models, AnimalDrug Evaluation, PreclinicalFemaleLungMiceMicrobial Sensitivity TestsAnti-Bacterial Agentsabscessusdrug testingmodelsmouseMycobacteriumpreclinical

Identifiers

PMID41004263
PMCPMC12587565

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.